Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463705 · ClinicalTrials.gov registry record · NA
Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications
A NA study of Diabetes and SGLT-2i and GLP-1RA Therapies, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 1,580
- Enrollment target
- 1
- Study location
NCT05463705: Completed NA study of Diabetes and SGLT-2i and GLP-1RA Therapies, sponsored by Brigham and Women's Hospital.
NCT05463705 is a NA study of Diabetes and SGLT-2i and GLP-1RA Therapies that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1,580 participants, below the 3,024-participant average among 338 other Diabetes trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05463705, a NA study of Diabetes and SGLT-2i and GLP-1RA Therapies, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,580 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the impact of addressing diffusion of responsibility with and without additional reduction of prescribing burden on SGLT-2i and GLP-1RAs prescribing compared to usual care. Population: MGH primary care physicians caring for at least 2 eligible patients. Eligible patients are individuals age18 years or older with type 2 diabetes and HbA1c \>7.5% and a compelling indication for an SGLT-2i or GLP-1RA (including cardiovascular disease, kidney disease, heart failure, or obesity), who are not already prescribed one of these therapies. Intervention: PCPs will be randomized to one of three arms: 1) intervention to address diffusion of responsibility, 2) Intervention to address diffusion of responsibility with additional simplification of prescribing, 3) usual care.
Primary Outcome
Electronic health record (EHR) prescribing data was used to identify the number of patients with prescriptions for SGLT-2i and GLP-1RA medications beginning 3 business days before the targeted patient visit and continuing through 28 days after the visit. The primary outcome only includes patients who attended the targeted visit.
Conditions Studied
Interventions
- BEHAVIORAL Intervention to address diffusion of responsibility
- BEHAVIORAL Intervention to address diffusion of responsibility + simplification of prescribing
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,580 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2024-08-22 |
| Phase | NA |
What the finished NCT05463705 record still lists
NCT05463705 is an interventional study that assigns participants to a tested intervention. Its 1,580 participants enrollment target places it among the larger protocols in the corpus, below the 3,024-participant average among 338 other Diabetes trials with a reported enrollment target (48% lower).
The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Intervention to address diffusion of responsibility is the first listed.
NCT05463705 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05463705 about?
NCT05463705 is a clinical study titled "Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications". This study will test the impact of addressing diffusion of responsibility with and without additional reduction of prescribing burden on SGLT-2i and GLP-1RAs prescribing compared to usual care. Population: MGH primary care physicians caring for at least 2 eligible patients. Eligible patients are in...
What is the current status of trial NCT05463705?
This trial is currently completed. It is a NA study. The enrollment target is 1,580 participants. The study started on 2023-05-04. Estimated completion is 2024-08-22.
What conditions does trial NCT05463705 study?
This clinical trial studies the following conditions: Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility, Prescribing Burden.
What interventions are being tested in trial NCT05463705?
The interventions under investigation include: Intervention to address diffusion of responsibility (BEHAVIORAL), Intervention to address diffusion of responsibility + simplification of prescribing (BEHAVIORAL).
Who is sponsoring clinical trial NCT05463705?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05463705 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05463705's enrollment target sits among peer trials
1,580 30th of 338 higher than 309 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT06445946 · 1,572 participants · Phase 4
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI